Page last updated: 2024-12-10

15(s)-15-methylprostaglandin e1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

15(S)-15-methylprostaglandin E1 (15(S)-15-methyl PGE1) is a synthetic analog of prostaglandin E1 (PGE1). Here's a breakdown:

**What it is:**

* **Prostaglandins (PGs)** are a class of lipids that act as signaling molecules within the body, involved in a wide range of physiological processes.
* **PGE1** is a specific prostaglandin with a variety of effects, including:
* Vasodilation (widening of blood vessels)
* Relaxation of smooth muscle
* Anti-inflammatory properties
* Stimulation of bone growth
* **15(S)-15-methyl PGE1** is a modified version of PGE1. It differs from the natural PGE1 by the addition of a methyl group at the 15th carbon position, specifically in the S configuration.

**Why it's important for research:**

1. **Enhanced Stability:** The methyl group modification increases the metabolic stability of PGE1, meaning it breaks down more slowly in the body. This makes it a more potent and longer-lasting drug candidate compared to natural PGE1.

2. **Improved Drug Delivery:** 15(S)-15-methyl PGE1 has better pharmacokinetic properties (how it gets absorbed, distributed, metabolized, and excreted) compared to PGE1. This makes it easier to deliver the drug to its target site.

3. **Potential Therapeutic Applications:** 15(S)-15-methyl PGE1 has been explored for various medical applications due to its enhanced potency and stability. Some areas of interest include:

* **Cardiovascular diseases:** It has been investigated as a potential treatment for heart failure, pulmonary hypertension, and peripheral artery disease due to its vasodilatory effects.
* **Gastrointestinal disorders:** It may be beneficial for conditions like Crohn's disease and ulcerative colitis due to its anti-inflammatory and mucosal protective properties.
* **Bone regeneration:** Its ability to stimulate bone growth makes it a promising agent for treating bone fractures and other bone-related disorders.

**Ongoing Research:**

Extensive research is ongoing to further explore the therapeutic potential of 15(S)-15-methyl PGE1 in various medical conditions. Scientists are investigating its efficacy, safety, optimal dosage, and potential side effects.

**Note:** While 15(S)-15-methyl PGE1 holds promise as a therapeutic agent, it is still under development and not currently available for clinical use.

15(S)-15-methylprostaglandin E1: stable deriv of PGE1; RN given refers to (11 alpha,13E,15S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5283057
CHEBI ID182984
SCHEMBL ID11069521
MeSH IDM0084231

Synonyms (20)

Synonym
CHEBI:182984
7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-3-methyloct-1-enyl]-5-oxocyclopentyl]heptanoic acid
9-oxo-11r,15s-dihydroxy-15-methyl-13e-prostaenoic acid
LMFA03010056 ,
15-methyl-15s-pge1
15-methyl-15s-prostaglandin e1
15(s)-15-methylprostaglandin e1
35700-26-6
prost-13-en-1-oic acid, 11,15-dihydroxy-15-methyl-9-oxo-, (11alpha,13e,15s)-
15(s)-15-methyl prostaglandin e1
SCHEMBL11069521
OMNFCPCBKCERJP-XBZFKEOQSA-N
9-oxo-11.alpha.,15s-dihydroxy-15-methylprost-13e-en-1-oic acid
HMS3648D09
prost-13-en-1-oic acid,11,15-dihydroxy-15-methyl-9-oxo-,(11a,13e,15s)-(9ci)
prost-13-en-1-oic acid,11,15-dihydroxy-15-methyl-9-oxo-, (11a,13e,15s)- (9ci)
sr-01000946409
SR-01000946409-1
DTXSID701148567
PD021164
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (82.61)18.7374
1990's4 (17.39)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.08 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]